The FTC’s complaint accuses Optum Rx and other pharmacy benefit managers of “abusing their economic power." Optum called the move a "baseless action."

Regulators say the nation's largest pharmacy benefit managers are partly to blame for the soaring cost of insulin in the U.S.

The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies of “engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs,

Months earlier, the agency released a report alleging the companies drove up the costs of some medications, including insulin.

Three companies that process about 80% of prescriptions in the United States — Caremark, Express Scripts and OptumRx — have engaged in anticompetitive practices that spur price increases, the

The Federal Trade Commission Friday announced it was suing the country's three biggest pharmacy benefit managers, claiming unfair practices inflated the cost of insulin.